<DOC>
	<DOCNO>NCT00408005</DOCNO>
	<brief_summary>This randomized phase III trial study different combination chemotherapy regimens side effect compare well work treat young patient newly diagnose T-cell acute lymphoblastic leukemia T-cell lymphoblastic lymphoma . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . It yet know combination chemotherapy regimen effective treat T-cell acute lymphoblastic leukemia T-cell lymphoblastic lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia T-cell Lymphoblastic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine , randomization , relative safety efficacy addition nelarabine ( Compound 506U78 ) augment Berlin-Frankfurt-MÃ¼nster ( BFM ) therapy ( Regimen C , Children 's Cancer Group [ CCG ] -1961 ) . II . To determine relative safety efficacy high dose methotrexate ( 5 g/m^2 ) leucovorin ( leucovorin calcium ) rescue compare escalate methotrexate without leucovorin rescue plus pegaspargase ( Capizzi I ) deliver interim maintenance . III . To gain preliminary data use nelarabine patient high risk T-cell lymphoblastic lymphoma effect long-term survival . SECONDARY OBJECTIVES : I . To determine relative safety efficacy withhold radiation patient low risk T-cell acute lymphoblastic leukemia ( T-ALL ) , treat Intermediate high risk patient 1200 cGy prophylactic cranial radiation . OUTLINE : INDUCTION THERAPY : ( week 1-5 ) Patients receive cytarabine intrathecally ( IT ) day 1 ; vincristine sulfate IV daunorubicin hydrochloride IV day 1 , 8 , 15 , 22 ; prednisone IV orally ( PO ) twice daily ( BID ) day 1-28 ; pegaspargase intramuscularly ( IM ) IV 1-2 hour day 4 , 5 , OR 6 ; methotrexate ( MTX ) IT day 8 29* . Patients Down syndrome ( DS ) also receive leucovorin calcium PO 48 60 hour MTX dose ( DS patient exclude 09/29/10 ) . After completion induction therapy , patient undergo risk assessment . Patients M1 marrow minimal residual disease ( MRD ) &lt; 1 % ( defined low- intermediate-risk ) proceed consolidation therapy day 36 blood count recover ( whichever occurs later ) . Patients M2 marrow ( 5-25 % blast ) and/or MRD &gt; = 1 % ( defined high-risk ) proceed consolidation therapy soon possible ( i.e. , wait day 36 blood count recover ) . Patients M3 marrow ( &gt; = 25 % blast ) ( define induction failure ) proceed consolidation therapy soon possible . NOTE : *Patients CNS3 disease also receive MTX IT day 15 22 . CONSOLIDATION THERAPY : ( week 6-13 ) During safety phase portion study , patient low-risk intermediate-risk disease randomize arm I III . Patients high-risk disease randomize arm I , II , III , IV . ( safety phase close accrual 09/29/10 ) During efficacy phase portion study , patient low-risk* disease randomize arm I III . Patients intermediate-risk high-risk** disease randomize arm I , II , III , IV . The safety phase end first 20 high-risk patient receive nelarabine evaluate . Patients DS nonrandomly assign arm I ( DS patient exclude 09/29/10 ) . Patients induction failure*** nonrandomly assign arm IV . NOTE : *Patients T-cell lymphoblastic lymphoma ( T-NHL ) nonrandomly assign arm I . NOTE : ** Patients T-NHL randomly assign arm I II without cranial radiotherapy . NOTE : *** Patients T-NHL nonrandomly assign arm II . ARM I : Patients receive MTX IT day 1 , 8 , 15 , 22* ; cyclophosphamide IV 30 minute day 1 29 ; cytarabine IV 15-30 minute subcutaneously ( SC ) day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO day 1-14 29-42 ; vincristine sulfate IV day 15 , 22 , 43 50 ; pegaspargase IM IV 1-2 hour day 15 43 . Patients persistent testicular disease DS testicular disease undergo testicular radiotherapy day 11-12 , 15-19 , 22-26 ( DS patient exclude 09/29/10 ) . Patients intermediate-risk high-risk disease ( CNS1 CNS2 ) undergo prophylactic cranial radiotherapy ( CRT ) ( 1,200 cGy/dose ) daily day 15-21 22-28 . Patients low-risk disease undergo CRT . NOTE : *Patients CNS3 disease omit MTX IT day 15 22 ; patient high-risk disease omit MTX IT day 1 add extra dose day 29 . ARM II : Patients receive nelarabine IV 60 minute day 1-5 43-47 ; MTX IT day 15 , 22* , 57 , 64 ; cyclophosphamide IV 30 minute day 8 50 ; cytarabine IV 15-30 minute SC day 8-11 , 15-18 , 50-53 57-60 ; oral mercaptopurine day 8-21 50-63 ; vincristine sulfate IV day 22 , 29 , 64 , 71 ; pegaspargase IM IV 1-2 hour day 22 64 . Patients persistent testicular disease DS testicular disease undergo testicular radiotherapy day 15 , 22-26 , 29-33 ( DS patient exclude 09/29/10 ) . Patients intermediate-risk high-risk disease ( CNS1 CNS2 ) undergo prophylactic CRT daily day 22-28 29-35 . NOTE : *Patients CNS3 disease omit MTX IT day 22 . ARM III : Patients receive MTX , cyclophosphamide , cytarabine , mercaptopurine , vincristine sulfate , pegaspargase arm I . Patients persistent testicular disease DS testicular disease undergo testicular radiotherapy arm I ( DS patient exclude 09/29/10 ) . ARM IV : Patients receive nelarabine , methotrexate , cyclophosphamide , cytarabine , mercaptopurine , vincristine sulfate , pegaspargase arm II . Patients persistent testicular disease DS testicular disease undergo testicular radiotherapy arm II ( DS patient exclude 09/29/10 ) . Once blood count recover , patient proceed interim maintenance therapy accord randomized/assigned arm . Patients achieve M1 marrow end consolidation therapy remove study . INTERIM MAINTENANCE THERAPY ( week 14-21 arm I III ; week 17-24 arm II IV ) : ARM I : Patients* receive vincristine sulfate IV escalating dos methotrexate IV day 1 , 11 , 21 , 31 , 41 ; pegaspargase** IM IV 1-2 hour day 2 22 ; methotrexate IT day 1 31 . Patients DS also receive leucovorin calcium PO 48 60 hour methotrexate IT dose ( DS patient exclude 09/29/10 ) . NOTE : * Patients T-NHL randomized assign arm I II . NOTE : **Patients allergy pegaspargase receive Erwinia asparaginase day 2 , 4 , 6 , 8 , 10 , 12 , 22 , 24 , 26 , 28 , 30 , 32 . ARM II : Patients* receive vincristine sulfate , escalate dos methotrexate , pegaspargase , methotrexate IT arm I . ARM III : Patients receive high-dose methotrexate ( HDMTX ) IV 24 hour vincristine sulfate IV day 1 , 15 , 29 , 43 ; mercaptopurine PO day 1-56 ; methotrexate IT day 1 29 . Beginning 42 hour start HDMTX , patient also receive leucovorin calcium IV orally every 6 hour 3 dos . ARM IV : Patients receive HDMTX , vincristine sulfate , mercaptopurine , methotrexate IT , leucovorin calcium arm III . Once blood count recover , patient proceed delay intensification therapy accord randomized/assigned arm . DELAYED INTENSIFICATION THERAPY ( week 22-30 arm I III ; week 25-33 arm II IV ) : ARM I : Patients* receive vincristine sulfate IV day 1 , 8 , 15 , 43 , 50 ; dexamethasone IV PO BID day 1-21 ( patient &lt; 10 year age ) OR day 1-7 15-21 ( patient &gt; = 10 year age patient DS ) ; doxorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 ; pegaspargase IM IV 1-2 hour day 4 , 5 , OR 6 , AND day 43 ; MTX IT day 1 , 29 , 36 ; cyclophosphamide IV 30 minute day 29 ; cytarabine IV 15-30 minute SC day 29-32 36-39 ; thioguanine PO day 29-42 . Patients DS also receive leucovorin calcium PO 48 60 hour methotrexate dose ( DS patient exclude 09/29/10 ) . NOTE : *T-NHL patient standard-risk nonrandomly assign arm I . ARM II : Patients** receive vincristine sulfate IV day 1 , 8 , 15 , 50 ; dexamethasone IV PO BID day 1-21 ( patient &lt; 10 year age ) OR day 1-7 15-21 ( patient &gt; = 10 year age ) ; doxorubicin hydrochloride IV 1-15 minute day 1 , 8 , 15 ; pegaspargase IM IV 1-2 hour day 4 , 5 , OR 6 AND day 50 ; methotrexate IT day 1 , 36 , 43 ; nelarabine IV 60 minute day 29-33 ; cyclophosphamide IV 30 minute day 36 ; cytarabine IV 15-30 minute day 36-39 43-46 ; thioguanine PO day 36-49 . NOTE : ** T-NHL patient induction failure nonrandomly assign arm II . ARM III : Patients receive vincristine sulfate , dexamethasone , doxorubicin hydrochloride , pegaspargase , methotrexate IT , cyclophosphamide , cytarabine , thioguanine arm I . Patients intermediate- high-risk disease ( CNS1 CNS2 disease ) undergo prophylactic CRT ( 1,200 cGy/dose ) QD day 50-54 57-59 . ARM IV : Patients receive vincristine sulfate , dexamethasone , doxorubicin hydrochloride , pegaspargase , methotrexate IT , nelarabine , cyclophosphamide , cytarabine , thioguanine arm II . Patients intermediate- high-risk disease ( CNS 1 CNS2 disease ) undergo prophylactic CRT day 50-54 57-59 . All patient CNS3 disease diagnosis undergo CRT ( 1,800cGy/dose ) QD day 50-54 57-61 . Once blood count recover , patient proceed maintenance therapy accord randomized/assigned arm . MAINTENANCE THERAPY ( week 31 end therapy arm I III ; week 34-69 arm II IV ) : ARM I : Patients* receive vincristine sulfate IV day 1 , 29 , 57 ; dexamethasone PO BID day 1-5 , 29-33 , 57-61 ; mercaptopurine PO QD day 1-84 ; methotrexate PO** day 8 , 15 , 22 , 29* , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; methotrexate IT day 1 . Treatment repeat every 84 day total duration study treatment 2 year start interim maintenance therapy ( approximately week 119 ) ( girls T-ALL ) 3 year start interim maintenance therapy ( approximately week 171 ) ( boy T-ALL ) . NOTE : * Patients T-NHL standard-risk nonrandomly assign arm I . NOTE : **Patients low-risk disease receive methotrexate IT , instead methotrexate PO , day 29 first 4 course therapy . ARM II : Patients*** receive vincristine sulfate IV day 1 57 ; dexamethasone PO day 1-5 57-61 ; mercaptopurine PO QD day 1-84 ; MTX PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; methotrexate IT day 1 ; nelarabine IV 60 minute day 29-33 . Treatment ( include nelarabine ) repeat every 84 day 3 course . Patients receive treatment ( without nelarabine ) follow : vincristine sulfate IV day 1 57 ; dexamethasone PO day 1-5 , 29-33 , 57-61 ; mercaptopurine PO day 1-84 ; methotrexate PO day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; methotrexate IT day 1 . Treatment ( without nelarabine ) repeat every 84 day total duration study treatment 2 year start interim maintenance therapy ( approximately week 121 ) ( girls T-ALL ) 3 year start interim maintenance therapy ( approximately week 173 ) ( boy T-ALL ) . NOTE : *** T-NHL patient induction failure nonrandomly assign arm II . ARM III : Patients receive vincristine sulfate , dexamethasone , mercaptopurine , methotrexate PO* , methotrexate IT arm I . Treatment repeat every 84 day total duration study treatment 2 year start interim maintenance therapy ( approximately week 119 ) ( girls T-ALL ) 3 year start interim maintenance therapy ( approximately week 171 ) ( boy T-ALL ) . NOTE : *Patients low-risk disease receive methotrexate IT , instead methotrexate PO , day 29 first 4 course therapy . ARM IV : Patients receive vincristine sulfate , dexamethasone , mercaptopurine , methotrexate PO , methotrexate IT , nelarabine arm II . Patients receive treatment ( without nelarabine ) follow : vincristine sulfate , dexamethasone , mercaptopurine , methotrexate PO , methotrexate IT arm II . Treatment ( without nelarabine ) repeat every 84 day total duration study treatment 2 year start interim maintenance therapy ( approximately week 121 ) ( girls T-ALL ) 3 year start interim maintenance therapy ( approximately week 173 ) ( boy T-ALL ) . After completion study therapy , patient follow periodically least 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>TALL patient must enrol AALL08B1 prior treatment enrollment AALL0434 Patients must newly diagnose TALL Tlineage lymphoblastic lymphoma ( TNHL ) stage IIIV ; Blineage lymphoblastic lymphoma eligible study ; diagnosis TALL establish leukemic blast lack myeloperoxidase evidence Blineage derivation ( cluster differentiation [ CD ] 19/CD22/CD20 ) , express either surface cytoplasmic CD3 two antigen CD8 , CD7 , CD5 , CD4 , CD2 CD1a ; surface CD3 express leukemic cell , additional marker immaturity , include transmission disequilibrium test ( TdT ) , CD34 CD99 assess expression ; case uncertain expression receive additional review within appropriate Children 's Oncology Group ( COG ) reference laboratory TNHL PATIENTS : For TNHL patient tissue available flow cytometry , criterion diagnosis analogous TALL ; tissue process mean ( i.e . paraffin block ) , methodology criterion immunophenotypic analysis establish diagnosis TNHL define submit institution accept Prior therapy restriction Patients shall prior cytotoxic chemotherapy exception steroid and/or IT cytarabine IT chemotherapy cytarabine allow prior registration patient convenience ; usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture ; ( Note : CNS status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment ) ; systemic chemotherapy must begin within 72 hour IT therapy Patients diagnose TNHL TALL respiratory distress hyperleukocytosis may require steroid prior initiation additional systemic therapy ; eligible AALL0434 stratify , base initial complete blood count ( CBC ) ; steroid pretreatment may alter risk group assessment ; TALL patient 's clinical status precludes lumbar puncture within 48 hour initiation steroid therapy , TALL patient CAN NOT classify low risk Intermediate high risk base result day 29 marrow ; patient TNHL receive steroid pretreatment classify high risk ; dose duration previous steroid therapy carefully document For management airway compromise , patient receive emergent chest irradiation 600 cGy eligible study Patients prior seizure disorder require anticonvulsant therapy eligible receive nelarabine ; addition , patient preexist grade 2 ( great ) peripheral neurotoxicity , determine prior Induction treatment treat physician neurologist , eligible receive nelarabine ; restriction eligibility design prevent excessive nelarabineinduced central peripheral neurotoxicity atrisk patient ; purpose study , include patient receive anticonvulsant therapy prevent/treat seizure prior two year Pregnant lactating female ineligible Patients Down syndrome ineligible enroll onto study For TNHL patient follow additional exclusion criterion apply : Bprecursor lymphoblastic lymphoma Morphologically unclassifiable lymphoma Absence Bcell Tcell phenotype marker case submit lymphoblastic lymphoma CNS3positive testicular involvement</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>